Lumeda is a clinical stage company working with leading cancer centers in the development and clinical evaluation of a therapeutic platform called DigiLum™ that is applicable to abdominal and thoracic cancers.  These account for over 60% of new cancer cases diagnosed globally that lead to over 70% of cancer-related mortalities. DigiLum™ is a drug-device combination administered intraoperatively that applies oxidative stress to targeted malignant tissue sites to drive multiple clinical results including tumor ablation, immunogenic cell death, and local tumor control in patients undergoing surgical resection. DigiLum™ presents a new paradigm in administration of photodynamic therapy that improves both the patient and provider experience in providing a safe, highly effective, targeted, and more tolerable therapy free of toxicities and side effects.